Nature Communications (May 2021)
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
- Xuqing Zhang,
- Mengyao Luo,
- Shamael R. Dastagir,
- Mellissa Nixon,
- Annie Khamhoung,
- Andrea Schmidt,
- Albert Lee,
- Naren Subbiah,
- Douglas C. McLaughlin,
- Christopher L. Moore,
- Mary Gribble,
- Nicholas Bayhi,
- Viral Amin,
- Ryan Pepi,
- Sneha Pawar,
- Timothy J. Lyford,
- Vikram Soman,
- Jennifer Mellen,
- Christopher L. Carpenter,
- Laurence A. Turka,
- Thomas J. Wickham,
- Tiffany F. Chen
Affiliations
- Xuqing Zhang
- Rubius Therapeutics, Inc.
- Mengyao Luo
- Rubius Therapeutics, Inc.
- Shamael R. Dastagir
- Rubius Therapeutics, Inc.
- Mellissa Nixon
- Rubius Therapeutics, Inc.
- Annie Khamhoung
- Rubius Therapeutics, Inc.
- Andrea Schmidt
- Rubius Therapeutics, Inc.
- Albert Lee
- Rubius Therapeutics, Inc.
- Naren Subbiah
- Rubius Therapeutics, Inc.
- Douglas C. McLaughlin
- Rubius Therapeutics, Inc.
- Christopher L. Moore
- Rubius Therapeutics, Inc.
- Mary Gribble
- Rubius Therapeutics, Inc.
- Nicholas Bayhi
- Rubius Therapeutics, Inc.
- Viral Amin
- Rubius Therapeutics, Inc.
- Ryan Pepi
- Rubius Therapeutics, Inc.
- Sneha Pawar
- Rubius Therapeutics, Inc.
- Timothy J. Lyford
- Rubius Therapeutics, Inc.
- Vikram Soman
- Rubius Therapeutics, Inc.
- Jennifer Mellen
- Rubius Therapeutics, Inc.
- Christopher L. Carpenter
- Rubius Therapeutics, Inc.
- Laurence A. Turka
- Rubius Therapeutics, Inc.
- Thomas J. Wickham
- Rubius Therapeutics, Inc.
- Tiffany F. Chen
- Rubius Therapeutics, Inc.
- DOI
- https://doi.org/10.1038/s41467-021-22898-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Red blood cells (RBCs) have unique properties that have been exploited for therapeutic uses. Here the authors engineer RBCs to co-express tumor associated antigens on MHC I, 4-1BBL and IL-12, generating artificial antigen presenting cells that can induce antigen-specific T cell responses and antitumor immune responses in preclinical models.
